Purpose Computer-based, patient-reported symptom survey tools have been described for patients undergoing chemotherapy. We hypothesized that patients undergoing radiotherapy might also benefit, so we developed a computer application to acquire symptom ratings from patients and generate summaries for use at point of care office visits and conducted a randomized, controlled pilot trial to test its feasibility. Methods Subjects were randomized prior to beginning radiotherapy. Both control and intervention group subjects completed the computerized symptom assessment, but only for the intervention group were printed symptom summaries made available before each weekly office visit. Metrics compared included the Global Distress Index (GDI), concordance of patient-reported symptoms and symptoms discussed by the physician and numbers of new and/or adjusted symptom management medications prescribed.
Introduction
A myriad of symptoms may be associated with cancer and compound the psychological and emotional toll a cancer diagnosis exerts on a patient and their loved ones. Approximately half of all cancer patients report pain, of whom approximately one third rate their pain as moderate or severe [1] . Non-pain-related symptoms including fatigue, mucositis, and nausea/vomiting likewise afflict many cancer patients and require active management in order to prevent a significant decline in quality of life [2] . Cancer treatment can often exacerbate existing symptoms or cause toxicities resulting in new or worsening symptoms [3] . With the increasing frequency of multi-modality regimens, optimizing patient-provider communication is a challenge to effectively recognizing and managing symptoms.
Previous research has shown that, although clinicians believe symptom management is important, they are often unaware of patients' symptoms. When patient-reported symptoms using the Quality of Life (QOL) Questionnaire QLQ-C30 were compared with concurrent physician-reported symptoms in the adverse event logs of a clinical trial, physicians were unaware of half the symptoms patients reported experiencing. Even more surprising was that half of the symptoms physicians were documenting were not reported by patients [4] . Inadequate management can result when physicians fail to recognize patient symptoms [5] , so measures taken to increase mutual understanding between physician and patient has the potential to greatly improve patient QOL during treatment.
Symptom and QOL assessment research has yielded valid and reliable measures of patient experience [6] [7] [8] , as well as strategies to best acquire and utilize this information in a clinical encounter [9] . Early work in this area has focused almost exclusively on oncology patients receiving chemotherapy [10] [11] [12] . Computer applications focused on chemotherapy patients' symptoms and quality of life have been shown to improve communication, mental health outcomes, and QOL [13] [14] [15] [16] . Such applications have not yet been validated for patients undergoing radiotherapy, and herein lies a gap in clinical care that merits attention. Up to two thirds of all cancer patients will receive some form of radiotherapy. Additionally, radiotherapy-related symptoms can be affected by the anatomic site, target volume, technique, dose, fractionation and duration of radiotherapy course, as well as the receipt of concurrent or neoadjuvant systemic therapies [17] [18] [19] [20] . Severe toxicity during radiotherapy can lead to the need for unplanned treatment breaks or premature cessation of therapy. This can have adverse radiobiologic consequences such as accelerated tumor cell repopulation [21] and adverse clinical consequences such as an estimated 1 % decrease in tumor control with every day radiation is delayed [22] .
To investigate the utility of computer-based patient-reported symptom surveys and summaries in the clinical setting, we developed a computer application that allows patients to electronically self-report their current symptoms and generates a printed report summarizing these data that the physician and patient can use in their weekly on-treatment visit (OTV) (Fig. 1) . We hypothesized that providing these reports could improve symptom management outcomes for radiotherapy patients as measured by increased concordance in physicianpatient communication, increased attempts by physicians to manage symptoms, or a lower total symptom burden. To test this, we designed a pilot single-institution randomized, controlled trial.
Methods

Developing and testing the computer application
We adapted a graphic user interface, previously developed for elderly patients receiving chemotherapy [23] , to run on a Windows-based PC. Question items determined through focus groups and interviews with radiation oncologists included Karnofsky Performance Status [24] , overall QOL, pain intensity in nine anatomic sites, 32 common cancer symptoms using both the Memorial Symptom Assessment Scale (MSAS)-Short Form [6, 25, 26] and zero to ten Numeric Rating Scales [27] , three skin damage items, the physical function scale from the EORTC QLQ-C30 [28] , and up to 12 items specific to 13 different cancers. We conducted pilot testing of 12 patients receiving radiotherapy to determine visual preference of graphic display and question architecture. Designed to run as a series of web pages, subjects used a touch-screen monitor to input their responses (Fig. 2) . The application then printed a report summarizing current symptoms and up to three previous time points (Fig. 3) . To measure patient-reported ease of use, we employed Davis' validated 8-item instrument designed for computerized questionnaires [29] .
Testing the computer application in a randomized pilot study Approval was obtained from the Institutional Review Board to carry out this pilot study. The aims were to demonstrate feasibility and generate the preliminary data necessary to obtain effect size estimates for the intervention on the polynomial slope coefficients in a random-effects regression model and subsequently design a fully powered randomized, controlled trial. A sample size of 100 was selected for this pilot study based on (i) feasibility, (ii) the ability to determine the appropriate polynomial model (i.e., linear versus quadratic), and (iii) give stable estimates of the parameter values (i.e., for the random-effects regression) with allowances for attrition over time.
Informed consent was obtained from all individual participants included in the study. The protocol is available in the Supplemental Materials. Subjects were enrolled prior to starting a new radiotherapy regimen for cancer and were randomized at the time of enrollment using blinded envelopes. Only patients with treatment regimens ≥4 weeks were recruited. The CONSORT diagram is shown in Fig. 1 . After enrollment but prior to initiation of radiation, patients were asked to fill out a questionnaire inquiring as to their level of education, employment status, whether or not they had ever used a touchscreen computer, how much computer experience they had (self-reported on a 5-point Likert scale from 1 = "none at all" to 5 = "very much"), and whether or not they would be willing to complete a survey as part of their usual care. Intervention group subjects completed the computerized symptom assessment and received a printed symptom summary before their weekly OTV with their radiation oncologists, who also received a copy of the summary. Control group subjects completed the same assessment, though printed symptom summaries were not provided to the patients or physicians. Intervention and control group subjects filled out the computerized symptom assessments in designated patient education cubicles just adjacent to the patient waiting area that were outfitted with touch-screen computers. Patients could 
Symptom quantification
The MSAS Global Distress Index (GDI) was used to collect and compare symptom data and is a reliable and valid measure consisting of the mean score of ten items, including four psychological symptoms (sadness, worry, irritability, and nervousness) and six physical symptoms (lack of appetite, lack of energy, feeling drowsy, constipation, dry mouth, and pain) [26] . Additional outcomes collected and compared included physician-patient concordance in communication about symptoms and the total number of symptom management prescriptions written by the radiation oncologists (a surrogate measure of overall efforts to manage symptoms). Concordance in physician-patient communication for symptoms was assessed by audio-recording the second or third OTV for a subset of patients. Recordings were coded by a blinded observer to identify every mention of a symptom by the physician, patient, or family member during the OTV. These mentioned symptoms were compared to the symptoms reported by the patient. Symptom management prescriptions were tracked in the patient's electronic medical record and included medications in the following classes: analgesics, muscle relaxers, steroids, antacids, anti-emetics, appetite stimulants, laxatives, anti-diarrheals, anti-depressants or anti-psychotics, sedative/hypnotics, skin care or mouth care products, and urinary or erectile dysfunction medications. The next three rows show scores for pain in different anatomic locations. The next nine rows show Memorial Symptom Assessment Scale (MSAS) scores. The following ten rows show skin toxicity symptoms, other sitespecific physical symptoms, and emotional and function scales. The bottom rows give a key to interpret the patient-reported outcomes (PROs) for symptoms, KPS, and QOL/pain control satisfaction
Data analysis
Pearson's chi-squared test was used for between-group comparisons of categorical variables, and Student's t test was used for between-group comparisons of continuous variables. All P values reported are two sided. The program Hierarchical Linear Modeling (HLM) 7 was used to examine the first four GDI scores over time. HLM involves data that vary at two levels: within individuals (level 1) and between individuals (level 1). At level 1, each patient's change in distress is represented by a trajectory captured by a set of unique parameters: intercept and slope. At level 2, these unique parameters become outcome variables to be explained by a set of predictors. The first step was to fit a level 1 model to capture the average pattern of change over time in the sample and the variance around the average. If significant variation existed, a level 2 model was examined to compare GDI scores across OTVs between the intervention and control groups, controlling for patient age, gender, and receipt of concurrent chemotherapy. For the audio-recorded office visit, we restricted our analysis to the 43 symptoms included in the computer application for all subjects. Concordance meant that a symptom selfreported by the patient using the computerized symptom assessment was mentioned or discussed in the office visit. We created Venn diagrams to illustrate the degree of concordance for patients in the intervention and control groups and performed sensitivity accounting for within-subjects correlation. 
Results
Patient and treatment characteristics
We approached 145 patients, 83 % consented, and 77 % participated for a total of 112 patients, including 54 control and 58 intervention subjects. In total, 109 (97.3 %) patients received radiotherapy with curative intent. Table 1 describes the demographics of the control and intervention groups.
Although not stratified by these characteristics, there were few differences between the control and intervention groups. However, significantly more patients in the intervention arm received concurrent chemotherapy (25 (43.1 %) vs. 13 (24.5 %); p = 0.04). Table 2 describes the radiotherapy details for the patients in the control and intervention groups.
Completion of the survey instrument
Subjects completed the computerized questionnaire in an average of 10.5 min (range 4-24 min). Ease-of-use was rated positively with an average score of +11.9 (SD = 4.1) on a scale of −16 to +16, with −16 indicating the hardest to use and +16 indicating the easiest to use.
Overall symptom burden
For the entire cohort, pain was reported at 80.3 % of all clinic visits; moderate and severe pain were reported at 34.9 and 12.1 % of all clinic visits, respectively. Other common symptoms were lack of energy (reported at 60.3 % of visits), dry mouth (35.3 %), difficulty sleeping (34.4 %), lack of appetite (30.6 %), urination problems (28.1 %), nausea (21.3 %), constipation (20.3 %), shortness of breath (11.8 %), and weight loss (13.1 %). The mean ± SD GDI scores from the control vs. intervention groups for weeks 1, 2, 3, and 4 are presented in Table 3 . HLM analysis found that a quadratic (non-linear) model fit the GDI data significantly better than a linear model (p < 0.001). The average slope was not significantly different from zero, but there was significant variability around the average slope (p < 0.001) indicating some patients increased in distress and others decreased over time. This significant variability appears to have led to an average change close to zero, reinforcing the IMRT intensity-modulated radiation therapy, 3D CRT three-dimensional conformal radiation therapy, 2D CRT two-dimensional conformal radiation therapy, cGy centigrey, SD standard deviation a Pearson's chi-squared test was used for between-group comparisons of categorical variables Comparing GDI as a measure of overall symptom burden between the intervention and control groups, the full level 2 HLM regression model with control vs. intervention group, age, gender, and chemo status included provided a significantly better fit to the data over an unconditional model with no predictors (p < 0.01). The intervention, however, did not produce a significant improvement in GDI over time. Receiving chemotherapy was significantly associated with higher distress scores at baseline only (p < 0.001). On the other hand, patient age was a significant predictor of change with younger patients experiencing faster increases in distress over time (p < 0.05) ( Table 4) .
Communication concordance
Forty-nine out of 112 (43.8 %) subjects agreed to have one of their OTVs audio-recorded including 26 in the control group and 23 in the intervention group. Concordance was significantly higher in the intervention group, with more symptoms reported by subjects using the computerized questionnaire being discussed in the subsequent office visit: 46/202 vs. 19/230. Using sensitivity accounting for within-subjects correlation yielded 23.2 vs. 10.3 % (p = 0.03). The most common symptoms that were reported by patients on the questionnaire but not subsequently discussed during the OTV were difficulty sleeping (control 12/211 (5.7 %), intervention 8/156 (5.1 %), overall 20/367 (5.5 %)) and pain in the neck or shoulders (control 10/211 (4.7 %), intervention 10/156 (6.4 %), overall 20/367 (5.5 %)). Conversely, the most common individual symptoms that were discussed during the OTV but not previously reported on the questionnaire were lack of energy (control 7/92 (7.6 %), intervention 7/59 (11.9 %), overall 14/151 (9.3 %)) and pinkness of the skin (control 9/92 (9.8 %), Unstandardized coefficients are shown *p < 0.05. **p < 0.001 a The program Hierarchical Linear Modeling (HLM) was used to examine the first four GDI scores over time. HLM involves data that vary at two levels: within individuals (level 1) and between individuals (level 2). At level 1, each patient's change in distress is represented by a trajectory captured by a set of unique parameters: intercept and slope. At level 2, these unique parameters become outcome variables to be explained by a set of predictors b The intercept has been coded to represent baseline scores
Control Group: N = 26 patients who consented to ontreatment-visit recording.
Intervention Group: N = 23 patients who consented to ontreatment visit recording Fig. 4 Venn diagrams and sensitivity accounting to show concordance between patientreported symptoms and symptoms discussed in weekly office visits for patients in the control and intervention groups. Because this analysis uses data from audio-taped patientphysician interactions, the samples size are the control n = 26 and intervention n = 23 intervention 5/59 (8.5 %), overall 14/151 (9.3 %)). There were no significant differences in symptoms reported but not discussed or vice versa between the control and intervention groups. The Venn diagrams in Fig. 4 show the relationship between reported and discussed symptoms.
Symptom management
A new medicine was started or dose adjusted at only 15.4 % (43/280) of control visits compared to 20.4 % (65/319) of intervention visits (p = 0.07). Pain management prescriptions were written or adjusted at 9.5 % of visits overall.
Discussion
This randomized, controlled pilot trial examined the longitudinal impact of providing patient-reported symptom summaries to radiotherapy patients and their clinicians in real-time.
The intervention did not result in improved trajectory of patient symptom burden as measured by the GDI. However, for intervention arm patients, there was an increased concordance between symptoms reported by the patients on computerized forms and symptoms discussed between the patient and physician at the weekly OTV. Additionally, there was a trend observed towards an increased physician symptom management prescribing for patients in the intervention arm. Patient-reported outcomes (PROs) are of increasing interest both in the clinical trial [30] as well as the clinic [31] settings. Computer-based symptom surveys have been described and evaluated as a means of utilizing technology to better facilitate gathering PRO data and delivering it to the care team for clinical decision-making [13] [14] [15] [16] . In order for a PRO survey to be effective, it must be easy for the patient to complete in a timely manner prior to their clinic visit. Subjects in our trial were able to complete the survey instrument in an average of 10.5 min, suggesting it could realistically be completed in the waiting room or exam room prior to the OTV. The majority of patients in both the control and intervention arms stated they would be willing to complete a similar survey in future clinical interactions, indicating barriers to patient "buy-in" to this process would likely be low.
Several lines of evidence suggest that receipt of printed symptom summaries may indeed improve physician practices in the radiation oncology clinic. Providing physicians with paper-based reminders during office visits has been shown to be an effective strategy for improving physician practices over several clinical conditions [32] . By sharing the printed symptom summaries with both the physician and the patient, it becomes a concrete platform for further discussion of symptoms and an aid to shared decision-making, which have also been suggested to positively influence physician practices [33] . It stands to reason that management of symptoms during cancer therapy is best accomplished when the treating physician and patient agree on the presence and severity of a patient's symptoms. Using discussion about patient-reported symptoms as a measure of this concordance, we found a paucity of overlap between the symptoms discussed and reported. The intervention group showed both an increase in symptom discussion concordance and the total number of symptoms discussed, suggesting that the printed summary is a useful tool in furthering this goal. We found that sleep disturbances as well as neck and shoulder pain were reported by patients in the questionnaire but not subsequently discussed with their physicians, while discussion of decreased energy and skin reaction were more likely to be discussed during an OTV even when these symptoms were not reported by the patient. In a fully powered trial, these trends could provide a valuable insight regarding symptoms experienced by patients and not routinely brought in discussions with their health-care providers as well as those that are addressed in the clinical discussion s e t t i n g b u t m i g h t b e m i s s e d b y e x i s t i n g P R O questionnaires.
Increased discussion of patient-reported symptoms alone is not sufficient to improve symptom control outcomes unless the discussion is translated into action. However, studies have shown physicians who are made aware of patientreported symptoms are more likely to act [11] . These results are consistent with our findings; intervention group patients received 32 % more symptom management prescriptions than control group patients. Because symptom management prescribing was infrequent, this result did not reach a statistical significance (p = 0.07) but would likely be significant in a fully powered study. Additionally, although we collected data regarding new and adjusted symptom management prescription medication, we did not capture data regarding referrals to other physicians or providers for symptom management including social work, nutrition, physical or occupational therapy, lymphedema therapy, speech and swallow therapy, nor did we capture discussion or recommendation of non-prescription medications for symptom control including. Therefore, we potentially underestimated the discussion of efforts taken to improve patient symptoms and improve QOL. Ultimately, we did not show a measurable improvement in patient symptoms as a result of our intervention. These results largely fall in line with other published results as well as a meta-analysis of electronic symptom reporting studies [34] . Although improved patient-physician communication is a noble goal, in planning future studies, emphasis should be placed on identifying interventions that lead to a measurable and meaningful improvement in patient symptoms.
This study provides a novel and valuable analysis on the effects of implementing a system of administering a computer-based patient-reported symptom survey and providing the patient and radiation oncologist with the resulting realtime feedback. However, it is not without limitations. This study involved a single institution and may not accurately reflect the practice patterns of physicians at other institutions. Second, this was a pilot study and thus not intentionally powered to produce significant results because effect sizes
were not yet known. Although the control and intervention groups were relatively well balanced, the groups were not stratified with regard to patient and treatment characteristics. More patients in the intervention group had head and neck or colorectal tumors, and more patients in the intervention group received concurrent chemotherapy. Both tumor location and concurrent therapy can affect the side effects of radiotherapy and may have also affected symptom discussion during OTVs as well as symptom management medication prescribing. Finally, we did not collect information regarding any differences in length of OTVs between the control and intervention groups. This would be an important metric to include in future studies as it would provide information as to whether computer-based symptom surveys and real-time feedback make clinic visits more efficient. Additionally, such data would conversely identify whether the implementation of this instrument requires significantly more provider time for each visit. Study strengths include the randomized, controlled design, rigorous symptom measurement and multi-level modeling analysis, and innovative approach to assessing communication and symptom management practices.
In conclusion, this pilot study demonstrates that a computer-based patient-reported symptom survey can be feasibly administered to cancer patients receiving radiotherapy prior to their weekly OTV with their treating physician. Additionally, our results suggest that printed summaries of patient-reported symptoms improves concordance between symptoms experienced by the patient and issues discussed during the office visit, and this improved communication may lead to a more active symptom management. Although the printed symptom summary did not result in improved trajectory of patient symptom burden, taken comprehensively, these findings suggest that this technology has real potential to improve patient outcomes if incorporated as part of a multimodal intervention. Future efforts will include implementation of a multi-center trial powered to answer the questions of whether or not patient symptom burden can be improved by utilization of this patient-reported symptom survey and providing real-time feedback to both patients and physicians.
